Press release content from Globe Newswire. The AP news staff was not involved in its creation. Basilea announces distribution agreement with JSC Lancet for antibiotic Zevtera® (ceftobiprole) ... Basilea Pharmaceutica AGJuly 14, 2021 GMT Ad hoc announcement pursuant to Art. 53 LR Basel, Switzerland, July 14, 2021 Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today that it has entered into an agreement with Moscow-based pharmaceutical company JSC Lancet for the distribution of Basilea’s antibiotic Zevtera® (ceftobiprole medocaril) in Russia, as well as in the other countries of the Eurasian Economic Union. Under the terms of the agreement, JSC Lancet is granted the exclusive right to register, distribute and commercialize Zevtera in the license territory, whilst Basilea will supply JSC Lancet with product at a transfer price. In addition, Basilea will receive an upfront payment and be eligible for sales milestone payments.